Pre-operative administration of sorafenib in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 12 May 2011 Planned end date changed from Jan 2011 to Jan 2012 as reported by ClinicalTrials.gov.